% 0期刊文章%一个彼得·达林顿% Ayal Rozenberg %一个Marie-Noelle Boivin % -福莱拉撒路%一个萨拉命名%一个简·里斯%易Ariel刘%杰弗里·科恩% Amit酒吧或% T人类间充质干细胞(MSC)相互地调节Th1和Th17反应:角色PGE2 (in8 - 2.005) % D J神经病学2012% % P in8 - 2.005 - in8 - 2.005 V % 78% N 1补充% X目的:检查一个潜在角色PGE2的人类MSC相互地调节效应T细胞反应的能力。首页背景人类自体MSC正在研究作为潜在的治疗多发性硬化(MS)患者。在女士,疾病活动被认为是由Th1和Th17效应T细胞。我们先前表明,上层清液(小口小口地饮)激活人类的MSC可以强劲增加Th17反应而降低Th1反应。PGE2在其他地方被牵连的互惠调节器Th1和Th17响应。设计/方法:PGE2含量的ELISA测定小口小口地饮的非活性,激活人类成人MSC。MSC的影响小口小口地饮对CD4 + Th1和Th17增殖和细胞因子反应相比,添加外源性PGE2的影响,或添加中和anti-PGE2抗体。结果:激活人类MSC的早期接触有限合伙人或IL-1β显著(p < 0.001)提高PGE2的MSC分泌。正如前面所示的,小口小口地饮从这些激活人类MSC相互地监管Th17(增加)和Th1(减少)的CD4 T细胞的反应。外生PGE2直接添加到T细胞显著增加Th17细胞增殖(p = 0.03),减少Th1细胞增殖(p = 0.028),伴随着IL-17A分泌和增加4倍大于4倍降低Th1细胞因子(IFNg)分泌。增加抗体中和anti-PGE2 MSC吃晚饭基本上废除(p < 0.001)诱导Th17反应的能力,但没有明显增加IFNg。结论:MSC暴露于炎性分子可以诱导Th17 T细胞反应通过PGE2依赖机制。的相互作用激活MSC小口小口地饮Th1和Th17反应可能反映的直接感应Th17 PGE2反应,和一个间接抑制Th1反应,二次IL-17感应。 Our mechanistic insights are of relevance as MSC are being considered therapeutically in MS patients.Supported by: NIH.Disclosure: Dr. Darlington has nothing to disclose. Dr. Rozenberg has nothing to disclose. Dr. Boivin has nothing to disclose. Dr. Cohen has received personal compensation for activities with Biogen Idec, Eli Lilly & Company, Novartis, and Vaccinex. Dr. Cohen has received research support for activities with Biogen Idec, BioMS, Genzyme Corporation, Novartis, Synthon, and Teva Neuroscience. Dr. Cohen has received personal compensation for activities with Biogen Idec, Eli Lilly & Company, Novartis, and Vaccinex. Dr. Cohen has received research support for activities with Biogen Idec, BioMS, Genzyme Corporation, Novartis, Synthon, and Teva Neuroscience. Dr. Cohen has received personal compensation for activities with Biogen Idec, Eli Lilly & Company, Novartis, and Vaccinex. Dr. Cohen has received research support for activities with Biogen Idec, BioMS, Genzyme Corporation, Novartis, Synthon, and Teva Neuroscience. Dr. Bar-Or has received personal compensation for activities with Aventis Pharmaceuticals, Bayhill Therapeutics, Biogen Idec, Berlex Laboratories, Eli Lilly & Company, Genentech, Inc., GlaxoSmithKline, Ono Pharmaceutical, Diogenix, Roche Diagnostics Corporation, Merck Serono, Novartis, Teva Neuroscience. Dr. Cohen has received personal compensation for activities with Biogen Idec, Eli Lilly & Company, Novartis, and Vaccinex. Dr. Cohen has received research support for activities with Biogen Idec, BioMS, Genzyme Corporation, Novartis, Synthon, and Teva Neuroscience. Dr. Bar-Or has received personal compensation for activities with Aventis Pharmaceuticals, Bayhill Therapeutics, Biogen Idec, Berlex Laboratories, Eli Lilly & Company, Genentech, Inc., GlaxoSmithKline, Ono Pharmaceutical, Diogenix, Roche Diagnostics Corporation, Merck Serono, Novartis, Teva Neuroscience.Wednesday, April 25 2012, 14:00 pm-18:00 pm %U